• Latest News
  • Freeline Secures over ¬£88 million of Funding¬†

    Freeline Therapeutics Ltd (“Freeline”), a clinical stage company focused on treatment of chronic systemic diseases with liver targeted adeno-associated virus (AAV) gene therapy, announces today that it has raised over £88 million of new capital in a Series B financing round. Syncona Ltd... read more


Funding Partners: